Saccharomyces cerevisiae RC12

Saccharomyces cerevisiae RC12 is a specific probiotic yeast strain containing beta-glucans and mannoproteins that interact with intestinal immune receptors to modulate gut immunity. While direct clinical evidence for RC12 is currently absent, closely related S. cerevisiae strains demonstrate measurable anti-inflammatory and pathogen-antagonistic activity through pattern recognition receptor engagement.

Origin & History

Saccharomyces cerevisiae RC12 is a specific clinical probiotic strain of baker's yeast, though no direct information about RC12's origin or production methods was found in available research. Related S. cerevisiae strains are typically isolated from natural fermentation sources like Korean nuruk and selected for probiotic properties such as acid and temperature resistance.

Historical & Cultural Context

No traditional medicinal use was identified for Saccharomyces cerevisiae RC12 specifically. Related strain SC28-7 was isolated from Korean nuruk, a traditional fermentation starter used in brewing, though selected for modern probiotic traits rather than historical medicinal applications.

Health Benefits

• No specific health benefits have been clinically studied for RC12 strain (evidence quality: none)
• Related strain SC28-7 reduced intestinal inflammation markers by up to 88% in mouse colitis models (evidence quality: preliminary animal data)
• Other S. cerevisiae strains demonstrated pathogen antagonism against E. coli O157:H7 in laboratory studies (evidence quality: preliminary in vitro)
• Some strains showed enhanced gut barrier proteins including mucin and tight junction proteins in animal models (evidence quality: preliminary)
• Better gastrointestinal survival compared to S. boulardii demonstrated for certain strains (evidence quality: preliminary in vitro)

How It Works

S. cerevisiae RC12 cell wall beta-1,3/1,6-glucans bind Dectin-1 receptors on intestinal dendritic cells and macrophages, triggering NF-κB and CARD9 signaling pathways that regulate pro- and anti-inflammatory cytokine production including IL-10 and TNF-α. Mannoproteins on the yeast surface interact with Toll-like receptor 2 (TLR2) and mannose-binding lectins, further shaping mucosal immune tone. These interactions collectively support epithelial barrier integrity by upregulating tight junction proteins such as occludin and claudin-1.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were found specifically for Saccharomyces cerevisiae RC12. Research is limited to related S. cerevisiae strains studied in preclinical models, including mouse colitis studies and in vitro gastrointestinal simulation experiments. No PubMed PMIDs were identified for RC12-specific research.

Clinical Summary

No published randomized controlled trials or human observational studies exist specifically evaluating the RC12 strain of S. cerevisiae. The closely related strain SC28-7 reduced intestinal inflammation markers by up to 88% in murine colitis models, representing preliminary animal data that cannot be directly extrapolated to humans. Broader S. cerevisiae research includes small human trials (typically n=20–80) documenting pathogen antagonism against Candida albicans and Clostridium difficile and modest improvements in stool consistency. The overall evidence base for RC12 specifically remains at the preclinical or inferential stage, and efficacy claims require strain-specific human trials before conclusions can be drawn.

Nutritional Profile

Saccharomyces cerevisiae RC12, as a probiotic yeast strain, shares the general compositional profile of S. cerevisiae with strain-specific variations. Dry cell weight basis: protein content approximately 40-50% (rich in all essential amino acids, particularly lysine ~7g/100g protein and leucine ~8g/100g protein); carbohydrates approximately 35-45% (predominantly beta-1,3/1,6-glucans in cell wall ~30% of dry weight, mannan polysaccharides ~20% of dry weight, intracellular glycogen and trehalose); lipids approximately 4-7% (primarily phospholipids and ergosterol, a precursor to vitamin D2). B-vitamin content is notable: thiamine (B1) ~1-10 mg/100g dry weight, riboflavin (B2) ~4-6 mg/100g dry weight, niacin (B3) ~30-50 mg/100g dry weight, pantothenic acid (B5) ~10-20 mg/100g dry weight, pyridoxine (B6) ~3-5 mg/100g dry weight, folate ~1-3 mg/100g dry weight, and biotin ~0.1-0.2 mg/100g dry weight. Minerals include zinc ~5-10 mg/100g dry weight, selenium (strain and growth medium dependent, potentially 50-200 mcg/100g), chromium, iron ~2-5 mg/100g dry weight, and magnesium ~50-80 mg/100g dry weight. Bioactive compounds include beta-glucans (immunomodulatory potential, bioavailability enhanced by processing), nucleotides (RNA content ~6-12% dry weight, providing purines and pyrimidines), glutathione ~100-200 mg/100g dry weight (antioxidant), and coenzyme Q10 in trace amounts. As a probiotic preparation, RC12 is delivered in viable cell form; bioavailability of nutrients is partially limited by intact cell wall structure unless cell disruption processing is applied. Specific quantitative compositional data published for the RC12 strain designation itself is not available in public literature; values cited reflect characterized S. cerevisiae reference ranges.

Preparation & Dosage

No clinically studied dosage ranges have been established for Saccharomyces cerevisiae RC12. Related probiotic yeasts like S. boulardii are typically dosed at 10^9 CFU/day, but no RC12-specific data exists. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other probiotic strains, Prebiotics (FOS, inulin), L-glutamine, Zinc carnosine, Digestive enzymes

Safety & Interactions

S. cerevisiae-based supplements are generally regarded as safe (GRAS) for immunocompetent adults at typical probiotic doses of 500 mg–5 g daily, but RC12-specific safety data are not published. Individuals with yeast allergies, Crohn's disease with anti-Saccharomyces cerevisiae antibodies (ASCA), or severely immunocompromised status should avoid use due to risk of hypersensitivity or rare fungal translocation. Concurrent use with antifungal drugs such as fluconazole or amphotericin B may reduce probiotic viability and efficacy. Pregnancy and lactation safety has not been evaluated for RC12 specifically; consultation with a healthcare provider is advised before use.